United Kingdom

Takara Bio Inc (4974.T)

4974.T on Tokyo Stock Exchange

2:29am GMT
Change (% chg)

¥-82 (-3.09%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
Monday, 9 Apr 2018 

April 9(Reuters) - Takara Bio Inc <4974.T>:Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takara's NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies.  Full Article

Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Takara Bio Inc <4974.T>:* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26 .  Full Article

Takara Holdings' subsidiary Takara Bio says merger between US-based units
Monday, 27 Mar 2017 

Takara Bio Inc <4974.T> : Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively . Says units Rubicon Genomics and WaferGen Bio-systems will be dissolved after transaction .Says the company, Takara Bio Inc, is a consolidated subsidiary of Takara Holdings Inc <2531.T>.  Full Article